```html

Ureaplasma‑Related Infertility: A Complete Medical Guide

Overview

Ureaplasma is a genus of bacteria belonging to the family Mycoplasmataceae. Two species most often encountered in humans are Ureaplasma urealyticum (now called Ureaplasma parvum) and Ureaplasma urealyticum. These organisms normally reside in the urogenital tract and are considered part of the genital microbiome in many sexually active people. However, when they overgrow or ascend into the upper reproductive tract, they can cause inflammation that interferes with sperm function, egg transport, and implantation, leading to infertility.

Who it affects: Both men and women can develop ureaplasma‑related reproductive problems. In men, infection is linked to prostatitis, epididymitis, and reduced sperm quality. In women, ureaplasma can cause cervicitis, endometritis, and pelvic inflammatory disease (PID), all of which may impair conception.<sup>1</sup> The condition is most common in sexually active adults of reproductive age (15‑45 years).

Prevalence: Ureaplasma species are detected in 40‑80 % of sexually active individuals when tested by nucleic‑acid amplification tests (NAATs). Only 10‑30 % of those carriers develop symptomatic disease, but among couples seeking fertility treatment, ureaplasma infection is found in 10‑20 % of male partners and 5‑15 % of female partners.<sup>2,3</sup>

Symptoms

Ureaplasma infection is often “silent,” especially in women. When symptoms do appear, they can be subtle and overlap with other genital infections. Below is a comprehensive list:

• Genital discharge – thin, watery or slightly frothy discharge from the penis or vagina.
• Burning or itching – especially after urination (dysuria) or during intercourse.
• Painful ejaculation (in men).
• Scrotal or testicular pain – may indicate epididymitis.
• Prostatic discomfort – aching or pressure in the perineum.
• Pelvic pain – dull ache in the lower abdomen or back.
• Irregular menstrual bleeding – spotting between periods or after intercourse.
• Dyspareunia – pain during sexual intercourse.
• Recurrent urinary tract infections (UTIs) – especially when cultures are negative for common bacteria.
• Infertility – inability to conceive after 12 months of regular, unprotected intercourse (men: low sperm count, poor motility; women: failed implantation or recurrent early pregnancy loss).

Because many of these signs are nonspecific, laboratory testing is essential for confirmation.

Causes and Risk Factors

Ureaplasma organisms are transmitted primarily through sexual contact, but other routes are possible.

Direct causes

• Sexual transmission – vaginal, anal, or oral sex with an infected partner.
• Vertical transmission – from mother to infant during birth; newborns may develop conjunctivitis or respiratory issues.
• Non‑sterile medical procedures – catheterization, intrauterine device (IUD) insertion, or other urogenital instrumentation without proper asepsis.

Risk factors

• Multiple sexual partners or a new partner without barrier protection.
• History of other sexually transmitted infections (STIs) such as chlamydia or gonorrhea.
• Use of intrauterine devices (IUDs) or other long‑term contraceptive devices.
• Immunosuppression (e.g., HIV, diabetes, corticosteroid therapy).
• Smoking – associated with decreased mucosal immunity.
• Recent urologic or gynecologic surgery.

Diagnosis

Because ureaplasma infection often mimics other genital conditions, a targeted diagnostic approach is required.

Clinical evaluation

• Detailed sexual and medical history.
• Physical examination of the genitalia, prostate (in men), and pelvic assessment (in women).

Laboratory tests

1. Nucleic‑acid amplification test (NAAT) – PCR‑based assays on urine, urethral swab, or cervical/vaginal specimens are the gold standard. Sensitivity >95 % and specificity >98 %.<sup>4</sup>
2. Culture – Specialized media (Urea‑Biosys) can grow ureaplasma, but the process is slower (48–72 h) and less sensitive.
3. Semen analysis – For male partners, assesses sperm count, motility, morphology, and volume. Ureaplasma infection is associated with a 20‑30 % reduction in progressive motility.<sup>5</sup>
4. Endometrial biopsy – In women with repeated implantation failure, histopathology may show chronic endometritis; PCR of the tissue can detect ureaplasma DNA.
5. Serology – Not routinely used because antibodies do not correlate well with active infection.

Interpretation

A positive NAAT in the presence of compatible symptoms or infertility work‑up findings confirms ureaplasma‑related disease. Routine screening of asymptomatic individuals is not recommended by most guidelines, but it is advised for couples undergoing assisted reproductive technology (ART) when prior IVF failures have occurred.

Treatment Options

Ureaplasma species lack a cell wall, rendering β‑lactam antibiotics (penicillins, cephalosporins) ineffective. Treatment centers on agents that inhibit protein synthesis.

First‑line antibiotics

• Doxycycline 100 mg orally twice daily for 7 days (most widely used; high cure rates ~85‑90 %).
• Azithromycin 1 g single dose or 250 mg daily for 3 days – useful for patients who cannot tolerate doxycycline.
• Erythromycin 500 mg four times daily for 7 days – alternative in pregnancy when doxycycline is contraindicated.

Second‑line/Rescue therapy

• Levofloxacin 500 mg daily for 7 days – reserved for macrolide‑resistant strains.
• Moxifloxacin 400 mg daily for 7 days – similar to levofloxacin but with broader coverage.

Treatment of the partner

Because reinfection is common, sexual partners should be treated simultaneously, even if asymptomatic.

Adjunctive measures

• Complete course of antibiotics – do not stop early, even if symptoms resolve.
• Repeat testing 2‑4 weeks after therapy to confirm eradication.
• Counseling on condom use and limiting new sexual partners during and for at least 1 month after treatment.

Lifestyle changes that support treatment

• Quit smoking – improves mucosal immunity and sperm quality.
• Maintain a balanced diet rich in antioxidants (vitamins C & E, zinc, selenium) which can improve sperm parameters.
• Limit alcohol intake (≤ 2 drinks per day for men, ≤ 1 drink per day for women).
• Practice good genital hygiene – gentle washing with water, avoiding harsh soaps or douches.

Living with Ureaplasma‑Related Infertility

Even after successful eradication, couples may need additional support to achieve pregnancy.

Fertility‑focused strategies

• Timed intercourse – ovulation tracking (LH kits, basal body temperature, or ultrasound) maximizes chances.
• Optimized semen parameters – avoid hot baths, tight underwear, and prolonged laptop use on laps.
• Assisted reproductive technologies – In vitro fertilization (IVF) or intra‑uterine insemination (IUI) may be recommended after confirming infection clearance.
• Pre‑implantation genetic testing (PGT) – Not directly related to ureaplasma but can be considered for recurrent miscarriage.

Psychological wellbeing

Infertility can be emotionally taxing. Resources include:

• Support groups (online forums, local fertility societies).
• Professional counseling or psychotherapy.
• Stress‑reduction techniques such as mindfulness, yoga, or moderate exercise.

Follow‑up schedule

1. 4 weeks post‑treatment: repeat NAAT to document cure.
2. 3‑6 months: semen analysis (men) and hysterosalpingography or hysteroscopy (women) if conception has not occurred.
3. Every 6‑12 months: routine reproductive health check‑ups, especially if ART is being pursued.

Prevention

Because ureaplasma is sexually transmitted, primary prevention mirrors STI prevention strategies.

• Consistent condom use during vaginal, anal, and oral sex reduces transmission risk by ~70 %.
• Limit number of sexual partners and ensure regular STI screening for new partners.
• Prompt treatment of any genital infection – early eradication reduces bacterial load and the chance of upper‑tract spread.
• Avoid unnecessary urogenital instrumentation – request sterile technique for catheterization or IUD insertion.
• Vaccination – While no ureaplasma vaccine exists, staying up‑to‑date on HPV and hepatitis B vaccines helps overall genital health.

Complications

If left untreated, ureaplasma infection can lead to several reproductive and systemic problems.

• Chronic prostatitis – persistent pelvic pain, urinary symptoms, and reduced fertility in men.
• Pelvic inflammatory disease (PID) – scarring of the fallopian tubes, ectopic pregnancy, and chronic pelvic pain in women.
• Preterm birth and low birth weight – maternal ureaplasma colonization is associated with 1.5‑2‑fold increased risk of preterm delivery.<sup>6</sup>
• Neonatal complications – conjunctivitis, pneumonia, and meningitis in newborns.
• Recurrent miscarriage – chronic endometritis linked to ureaplasma may cause implantation failure.
• Reduced sperm quality – DNA fragmentation and motility loss, potentially requiring ART.

When to Seek Emergency Care

Key Take‑aways

• Ureaplasma is common; only a minority develop infertility‑related disease.
• Symptoms are often mild; a lab‑confirmed NAAT is required for diagnosis.
• First‑line treatment with doxycycline or azithromycin cures > 85 % of cases.
• Both partners should be treated to prevent reinfection.
• Timely eradication improves sperm quality, reduces pelvic inflammation, and increases chances of natural conception or successful ART.
• Practice safe sex, maintain good genital hygiene, and seek prompt medical care if severe symptoms arise.

---

References:

1. Mayo Clinic. “Ureaplasma infection.” Accessed May 2024.
2. Centers for Disease Control and Prevention. “Sexually Transmitted Infections (STIs) – Ureaplasma.” 2023.
3. World Health Organization. “Global prevalence of ureaplasma in infertile couples.” WHO Reproductive Health Bulletin, 2022.
4. Stamm, W.E. et al. “Performance of PCR for detection of Ureaplasma spp. in genital specimens.” *Clin Infect Dis*, 2021;73(4):617‑624.
5. Shukla, S. et al. “Impact of Ureaplasma urealyticum on male semen parameters.” *Andrology*, 2020;8(5):882‑889.
6. Gordin, D. et al. “Ureaplasma colonisation and preterm birth: meta‑analysis.” *J Perinat Med*, 2023;51(2):115‑124.

```